Metastatic castration-resistant prostate cancer patients have very few options left for them in medical care. Nuclear medicine therapy with 177 Leutitum PSMA is used in these patients for palliation of symptoms, improvement in the quality of life and to improve progression-free survival.

In our department, we have treated many people with these therapies and found improvement in symptoms, quality of life and have found improvement in survival in the majority of them.